In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come ...

Eli Lilly CEO David Ricks, also an Adobe director, paid $1 million on Jan. 28 for 2,250 shares of the software company.

FY25 saw AdAlta (ASX:1AD) focus on increasing its corporate muscle, with two new board members and additional advisors ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

Eli Lilly and Company announced that its board has authorized a stock buyback ... Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something ... on the Move Benzinga Edge's Unusual Options board spots potential market movers before they ...

When the researchers spoke with care partners involved in this research, some mentioned they noticed changes in behaviours following the trial, such as the patient calling family members when they ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...